Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effective in June 2024 $237.0 million in cash and cash equivalents and marketable securities to advance clinical programs and portfolio to mid-2026 CAMBRIDGE, Mass. & MONTREAL, May 07, 2024 BUSINESS WIRE )--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024. "This was a quarter of clinical progress as we await key, near-term data on a rich set of distinctive clinical appro
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX) [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsBusiness Wire
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition [Yahoo! Finance]Yahoo! Finance
- Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionBusiness Wire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/26/24 - Form 8-K
- RPTX's page on the SEC website